MeSH term
Frequency | Condition_Probility | Adult | 31 | 0.0 |
Humans | 169 | 0.0 |
Male | 31 | 0.0 |
Middle Aged | 22 | 0.0 |
Reference Values | 3 | 0.0 |
Risk Factors | 2 | 0.0 |
Aged | 15 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Comparative Study | 25 | 0.0 |
Dose-Response Relationship, Drug | 12 | 0.0 |
Female | 38 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 103 | 0.0 |
Tumor Cells, Cultured | 19 | 0.0 |
Antigens, CD/blood | 2 | 0.0 |
Cytokines/*pharmacology | 8 | 2.0 |
Interleukin-3/pharmacology | 25 | 9.0 |
Ploidies | 2 | 0.0 |
Recombinant Proteins/pharmacology | 19 | 1.0 |
Thrombopoietin/*pharmacology | 3 | 3.0 |
Animals | 61 | 0.0 |
Apoptosis/*genetics | 2 | 0.0 |
Chromosome Painting | 2 | 4.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 6 | 8.0 |
Karyotyping | 5 | 0.0 |
Mice | 36 | 0.0 |
Mutation | 4 | 0.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Transfection | 13 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 35 | 0.0 |
Adolescent | 8 | 0.0 |
Base Sequence | 13 | 0.0 |
Child | 6 | 0.0 |
DNA Primers | 2 | 0.0 |
Interleukin-3/*genetics | 4 | 44.0 |
*Chromosome Mapping | 4 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Rats | 5 | 0.0 |
Acute Disease | 5 | 0.0 |
Cell Division/*drug effects | 2 | 0.0 |
Interleukin-3/*pharmacology | 18 | 14.0 |
Protein Binding | 2 | 0.0 |
Stem Cells/*drug effects | 2 | 14.0 |
Amino Acid Sequence | 8 | 0.0 |
Cell Division | 17 | 0.0 |
Cell Line | 21 | 0.0 |
Models, Molecular | 3 | 0.0 |
Molecular Sequence Data | 15 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Receptors, Interleukin-3/*chemistry | 2 | 100.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Signal Transduction | 3 | 0.0 |
Cell Survival/drug effects | 5 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 4 | 2.0 |
Antigens, CD34/analysis | 7 | 1.0 |
Cell Culture Techniques | 4 | 0.0 |
Cell Division/drug effects | 22 | 0.0 |
Culture Media/pharmacology | 3 | 3.0 |
Cytokines/pharmacology | 4 | 1.0 |
Graft Survival | 2 | 0.0 |
Growth Substances/pharmacology | 3 | 1.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 6 | 10.0 |
Immunophenotyping | 7 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Erythropoietin/*pharmacology | 4 | 3.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Interleukin-2/pharmacology | 6 | 1.0 |
*Milk Proteins | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
Signal Transduction/drug effects | 3 | 0.0 |
Cells, Cultured | 43 | 0.0 |
Coculture Techniques | 2 | 0.0 |
Fetal Blood/*cytology | 5 | 2.0 |
Flow Cytometry | 11 | 0.0 |
English Abstract | 14 | 0.0 |
*Hematopoiesis | 3 | 1.0 |
Hematopoietic Stem Cells/cytology | 3 | 3.0 |
Recombinant Proteins/*pharmacology | 2 | 2.0 |
Cell Differentiation/drug effects | 11 | 1.0 |
Biological Markers | 2 | 0.0 |
Cell Lineage | 2 | 0.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 5 | 3.0 |
*Hematopoiesis/drug effects | 3 | 18.0 |
Infant, Newborn | 5 | 0.0 |
Interleukin-6/pharmacology | 5 | 1.0 |
Stem Cell Factor/pharmacology | 7 | 4.0 |
Stromal Cells/cytology | 3 | 6.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Tumor Stem Cell Assay | 5 | 2.0 |
Cytokines/*genetics | 3 | 2.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/genetics | 2 | 7.0 |
Interleukin-4/genetics | 2 | 5.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 12 | 3.0 |
Hematopoiesis/drug effects | 3 | 3.0 |
Membrane Proteins/pharmacology | 4 | 9.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Hematopoiesis/*physiology | 3 | 3.0 |
*Lymphocyte Activation | 2 | 0.0 |
T-Lymphocytes/*immunology | 4 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Antigens, CD34/*analysis | 2 | 0.0 |
*Cell Division | 2 | 1.0 |
Child, Preschool | 4 | 0.0 |
Hematopoietic Stem Cells/*cytology/immunology | 2 | 2.0 |
Neoplasms/pathology | 2 | 7.0 |
Phenotype | 7 | 0.0 |
Colony-Forming Units Assay | 22 | 3.0 |
DNA Primers/genetics | 2 | 0.0 |
In Vitro | 18 | 0.0 |
Species Specificity | 3 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*immunology | 2 | 25.0 |
Interleukin-3/*immunology | 2 | 66.0 |
Antigens, CD/*analysis | 4 | 0.0 |
Hematopoietic Stem Cells/*drug effects/immunology | 2 | 40.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Cell Culture Techniques/methods | 4 | 1.0 |
Cell Culture Techniques/*methods | 3 | 3.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Hematopoietic Stem Cells/*cytology | 7 | 3.0 |
Kinetics | 7 | 0.0 |
Pregnancy | 3 | 0.0 |
Hematopoietic Stem Cell Transplantation | 2 | 1.0 |
Cell Count | 3 | 0.0 |
Megakaryocytes/*pathology | 2 | 6.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Time Factors | 6 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Plasmids | 2 | 0.0 |
Recombinant Proteins/therapeutic use | 3 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Growth Substances/*pharmacology | 6 | 1.0 |
Stimulation, Chemical | 4 | 0.0 |
Drug Synergism | 6 | 0.0 |
Hematopoiesis/drug effects/physiology | 2 | 33.0 |
Interleukin-3/*physiology | 2 | 13.0 |
Oxidation-Reduction | 2 | 0.0 |
Histamine Release/*drug effects | 5 | 17.0 |
Immunoglobulin E/immunology | 3 | 5.0 |
Tetradecanoylphorbol Acetate/pharmacology | 6 | 0.0 |
Hematopoietic Stem Cells/*immunology | 2 | 1.0 |
Administration, Oral | 2 | 0.0 |
Antibodies, Anti-Idiotypic/pharmacology | 2 | 6.0 |
Antigens, CD34/*blood | 2 | 2.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Bone Marrow/*metabolism | 4 | 8.0 |
*Bone Marrow Cells | 9 | 3.0 |
Cattle | 3 | 0.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Megakaryocytes/*cytology | 3 | 5.0 |
Eosinophil Peroxidase | 3 | 5.0 |
Interleukin-5/pharmacology | 2 | 7.0 |
Basophils/*drug effects | 2 | 28.0 |
Concanavalin A/pharmacology | 2 | 0.0 |
Diagnosis, Differential | 4 | 0.0 |
Genetic Markers | 2 | 0.0 |
Cytokines/biosynthesis | 2 | 0.0 |
Cell Differentiation | 5 | 0.0 |
Growth Substances/*physiology | 2 | 1.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Antibodies, Monoclonal | 6 | 0.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
*Proto-Oncogenes | 2 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Lymphocyte Activation | 4 | 0.0 |
Monocytes/cytology | 2 | 1.0 |
Chromosome Mapping | 5 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Receptors, Erythropoietin/metabolism | 2 | 6.0 |
Receptors, Interleukin-2/genetics/metabolism | 2 | 14.0 |
Phytohemagglutinins/pharmacology | 3 | 0.0 |
T-Lymphocytes/cytology | 2 | 2.0 |
Infant | 3 | 0.0 |
Culture Media, Serum-Free | 3 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Gene Expression | 8 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Hematopoietic Stem Cells/drug effects | 2 | 3.0 |
Hematopoietic Stem Cells/*drug effects | 5 | 7.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Cytokines/*therapeutic use | 2 | 11.0 |
Granulocyte Colony-Stimulating Factor/therapeutic use | 2 | 3.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use | 2 | 7.0 |
Growth Substances/genetics | 2 | 3.0 |
Prospective Studies | 2 | 0.0 |
Transplantation, Autologous | 2 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Bone Marrow | 2 | 5.0 |
Hela Cells | 2 | 0.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Cell Separation | 3 | 0.0 |
Hematopoietic Cell Growth Factors/*pharmacology | 4 | 8.0 |
Phosphorylation | 3 | 0.0 |
Antigens, CD34 | 5 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/physiology | 2 | 7.0 |
Interleukin-3/physiology | 5 | 17.0 |
Interleukin-5/physiology | 3 | 30.0 |
Calcimycin/pharmacology | 4 | 1.0 |
Interleukin-3/*metabolism | 2 | 40.0 |
Tumor Necrosis Factor-alpha/pharmacology | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Antigens, CD/analysis | 2 | 0.0 |
Bone Marrow Cells | 8 | 1.0 |
Platelet Count | 2 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Asthma/*immunology | 2 | 2.0 |
Depression, Chemical | 2 | 1.0 |
Colony-Stimulating Factors/*pharmacology | 4 | 8.0 |
Drug Interactions | 2 | 0.0 |
Erythropoietin/pharmacology | 3 | 2.0 |
Interleukin-2/*pharmacology | 3 | 1.0 |
Stem Cell Factor | 2 | 2.0 |
Interleukin-3/therapeutic use | 2 | 33.0 |
Monocytes/*immunology | 2 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Hematopoiesis | 2 | 0.0 |
Interleukins/pharmacology | 2 | 2.0 |
Blotting, Southern | 2 | 0.0 |
Hamsters | 3 | 0.0 |
Hybrid Cells | 3 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
*Chromosomes, Human, Pair 5 | 6 | 2.0 |
Polycythemia Vera/blood/*diagnosis | 2 | 40.0 |
Interleukin-3/biosynthesis | 2 | 22.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Receptors, Interleukin-2/metabolism | 2 | 1.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
B-Lymphocytes | 2 | 1.0 |
Down-Regulation | 2 | 0.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Culture Media, Serum-Free/*pharmacology | 2 | 25.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Interleukin-6/*pharmacology | 2 | 0.0 |
Antigens, CD4/analysis | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 2 | 1.0 |
CHO Cells | 2 | 0.0 |
Eosinophils/physiology | 2 | 15.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
DNA Probes | 2 | 0.0 |
Cytokines | 4 | 3.0 |
Granulocyte Colony-Stimulating Factor | 2 | 10.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 3.0 |
Recombinant Proteins | 2 | 0.0 |
Stem Cells/*cytology | 2 | 2.0 |
Colony-Stimulating Factors/pharmacology | 2 | 4.0 |
Erythropoiesis/drug effects | 2 | 4.0 |
Hematopoiesis/*drug effects | 3 | 3.0 |
Cell Division/physiology | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Transforming Growth Factors | 2 | 2.0 |
Structure-Activity Relationship | 2 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
